托吡酯治疗双相障碍躁狂发作的疗效分析及安全性评价  

THE EFFECT ANALYSIS OF TOPIRAMATE IN TREATMENT OF PATIENTS WITH BIPOLAR MANIC AND ITS SAFETY EVALUATION

作　　者：李正发[1] 

机构地区：[1]四川省南充精神卫生中心,南充637000

出　　处：《现代预防医学》2010年第23期4546-4547,共2页Modern Preventive Medicine

摘　　要：[目的]观察托吡酯治疗双相障碍躁狂发作的临床疗效分析及对安全性进行评价。[方法]2009年1月~2010年1月期间,62例双相障碍躁狂发作患者随机分为两组,观察组31例采用托吡酯和对照组31例采用碳酸锂,比较治疗前后的临床疗效、BRMS和CGI-SI评分比较和不良反应的发生情况。[结果]观察组的总有效率为77.4%,对照组的总有效率为83.9%,两组比较差异无统计学意义（P﹥0.05）。两组治疗后BRMS和CGI-SI评分均较治疗前明显下降,差异有统计学意义（P﹤0.05）。但两组治疗后BRMS和CGI-SI评分比较,差异无统计学意义（P﹥0.05）。观察组不良反应发生率明显低于对照组（P﹤0.05）。[结论]托吡酯对双相障碍躁狂发作的疗效治疗的疗效与传统药物相当,能够明显降低患者BRMS和CGI-SI评分,并且不良反应发生率低,值得在临床推广应用。[Objective]To observe the clinical effect of topiramate in treatment of patients with bipolar manic and evaluate its safety.[Methods]From January 2009 to January 2010,62 cases of bipolar manic patients were randomly classified into two groups,observation group with 31 cases was treated with topiramate and control group with 31 cases was treated with lithium.The clinical effects,scores of BRMS and CGI-SI,adverse effects were compared.[Results]The total effective rate in observation group was 77.4% and the total effective rate in observation group was 83.9%.There was no significant difference between the two groups（P﹥0.05）.Compared with pre-treatment,scores of BRMS and CGI-SI in both groups were significantly decreased after treatment（P﹤0.05）,but there was no significant difference between the two groups（P﹥0.05）.The adverse reaction rate in observation group was significantly lower than that in control group（P﹤0.05）.[Conclusion]Topiramate in treatment with bipolar manic has the similar curative effect,which can reduce the scores of BRMS and CGI-SI and adverse reactions rate.

关 键 词：托吡酯 双相障碍躁狂发作 安全性 

分 类 号：R749.41[医药卫生—神经病学与精神病学]